Skip to content

Iterum Therapeutics plc

ITRMF

CIK 0001659323

← back to feed
Revenue (TTM)
$866K
Q3 Sep 2025
Net Income (TTM)
−$26.47M
+35.4% YoY Q3 Sep 2025
EPS Diluted (TTM)
−$0.80
+57.4% YoY Q3 Sep 2025
Gross Margin
—
Q3 Sep 2025
Operating Margin
-2,523.9%
Q3 Sep 2025
Net Margin
-3,056.9%
Q3 Sep 2025
Free Cash Flow (TTM)
−$29.14M
Q3 Sep 2025
Cash
$11M
Q3 Sep 2025
Total Debt
$13.08M
Q3 Sep 2025
Shares Outstanding
44.66M sh
Q3 Sep 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings